A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
中重度急性呼吸窘迫综合征的恒定自然杀伤 T 细胞疗法的 1/2 期临床试验
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-024-44905-z
Terese C Hammond #, Marco A Purbhoo #, Sapana Kadel, Jerome Ritz, Sarah Nikiforow, Heather Daley, Kit Shaw, Koen van Besien, Alexandra Gomez-Arteaga, Don Stevens, Waldo Ortuzar, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Reed Masakayan, Burcu Yigit, Shannon Boi, Kah Teong Soh, John Chamberlan
